Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC

Cited by (1,002)

Items 701–800 of 1,002

1. Superior efficacy of immunotherapy‐based combinations over monotherapy for EGFR ‐mutant non‐small cell lung cancer acquired resistance to EGFR‐TKIs
   Lu Yang, Xuezhi Hao, Xingsheng Hu, Zhijie Wang, Ke Yang, Yuling Mi, Yaning Yang, Haiyan Xu, Guangjian Yang, Yan Wang · 2020 · Thoracic Cancer
2. Tetracyclines increase the survival of NSCLC patients treated with EGFR TKIs: a retrospective nationwide registry study
   Virve Alanen, Sanna Iivanainen, Martti Arffman, Jussi Pekka Koivunen · 2020 · ESMO Open
3. The evolving paradigm of biomarker actionability: Histology-agnosticism as a spectrum, rather than a binary quality
   Paolo Tarantino, Luca Mazzarella, Antonio Marra, Dario Trapani, Giuseppe Curigliano · 2021 · Cancer Treatment Reviews
4. Reduced PHLPP Expression Leads to EGFR-TKI Resistance in Lung Cancer by Activating PI3K-AKT and MAPK-ERK Dual Signaling
   Wei Wang, Xinhang Xia, Kuifei Chen, Chen Meng, Yinnan Meng, Dongqing Lv, Haihua Yang · 2021 · Frontiers in Oncology
5. Effect of timing, technique and molecular features on brain control with local therapies in oncogene-driven lung cancer
   Rami Ateyah El Shafie, Katharina Seidensaal, Farastuk Bozorgmehr, Daniel N. Kazdal, Tanja Eichkorn, Mariam Elshiaty, Dorothea Weber, Michael Allgäuer, Laila König, Kristin Lang et al. · 2021 · ESMO Open
6. Antibody Drug Conjugates in Lung Cancer: State of the Current Therapeutic Landscape and Future Developments
   Joshua E. Reuss, Laura Gosa, Stephen V. Liu · 2021 · Clinical Lung Cancer
7. Contribution of the IdyllaTM System to Improving the Therapeutic Care of Patients with NSCLC through Early Screening of EGFR Mutations
   Constance Petiteau, Gwladys Robinet-Zimmermann, Adèle Riot, Marine Dorbeau, Nicolas Richard, Cécile Blanc‐Fournier, Frédéric Bibeau, Simon Deshayes, Emmanuel Bergot, R. Gervais et al. · 2021 · Current Oncology
8. Health and Budget Impact of Liquid-Biopsy-Based Comprehensive Genomic Profile (CGP) Testing in Tissue-Limited Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients
   Yuti P. Patel, Don Husereau, Natasha B. Leighl, Barbara L. Melosky, Julian Nam · 2021 · Current Oncology
9. Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
   Qingli Cui, Yanhui Hu, Qingan Cui, Daoyuan Wu, Yuefeng Mao, Dongyang Ma, Huaimin Liu · 2022 · Frontiers in Pharmacology
10. Treatment-Related Adverse Events of Combination EGFR Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor in EGFR-Mutant Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
    D. Chan, Cheuk‐Wai Choi, Victor Ho-Fun Lee · 2022 · Cancers
11. Combining EGFR-TKI With SAHA Overcomes EGFR-TKI-Acquired Resistance by Reducing the Protective Autophagy in Non-Small Cell Lung Cancer
    Peijun Cao, Li Y, Ruifeng Shi, Yuan Yin, Hao Gong, Guangsheng Zhu, Zihe Zhang, Chen Chen, Hongbing Zhang, Minghui Liu et al. · 2022 · Frontiers in Chemistry
12. FGFR1 promotes tumor immune evasion via YAP-mediated PD-L1 expression upregulation in lung squamous cell carcinoma
    Min M. Lu, Kaixuan Wang, Wenxiang Ji, Yongfeng Yu, Ziming Li, Weiliang Xia, Shun Lu · 2022 · Cellular Immunology
13. Histomolecular Resistance Mechanisms to First-Line Osimertinib in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Multicentric Retrospective French Study
    Assya Akli, Nicolas Girard, Vincent Fallet, G. Rousseau-Bussac, Valérie Gounant, Sylvie Friard, Jean Trédaniel, Cécile Dujon, Marie Wislez, Boris Duchemann et al. · 2022 · Targeted Oncology
14. Association of smoking status with non-small cell lung cancer patients harboring uncommon epidermal growth factor receptor mutation
    How‐Wen Ko, Shian‐Sen Shie, Chih‐Wei Wang, Chi‐Tsun Chiu, Chih-Liang Wang, Tsung‐Ying Yang, Shou-Chu Chou, Chien‐Ying Liu, Chih‐Hsi S. Kuo, Yu‐Ching Lin et al. · 2022 · Frontiers in Immunology
15. Variation in Use of Lung Cancer Targeted Therapies Across State Medicaid Programs, 2020-2021
    Thomas J. Roberts, Aaron Seth Kesselheim, Jerry Avorn · 2023 · JAMA Network Open
16. Cost‐effectiveness analysis of osimertinib plus chemotherapy for patients with EGFR ‐mutated advanced non‐small cell lung cancer
    Wentao Tian, Lishui Niu, Rongrong Zhou, Ziqi Wang, Jiaoyang Ning, Ruoyu Lu, Yin Shi, Zhaohua Tan · 2024 · Cancer Medicine
17. Dose optimisation to improve access to effective cancer medicines
    Ian F. Tannock, Elisabeth G.E. de Vries, Antonio Tito Fojo, Marc E Buyse, Lorenzo Moja · 2025 · The Lancet Oncology
18. Lung Cancer and Cardiovascular Disease
    Malak El-Rayes, Inbar Nardi Agmon, Christopher Yu, Nichanan Osataphan, Helena Alexandra Yu, Andrew J. Hope, Adrian Gerold Sacher, Anthony Francis Yu, Husam Mohamed Abdel-Qadir, Paaladinesh Thavendiranathan · 2025 · JACC CardioOncology
19. The 2024 International Association for the Study of Lung Cancer Global Survey on Biomarker Testing
    Matthew P. Smeltzer, Jennifer C. King, Casey Connolly, Kristin Brunson, Maiyan Chau, Shuyan Chen, Anna Kerpel-Fronius, Sylvie Lantuéjoul, Anant Mohan, Allison P. Plaxco et al. · 2025 · Journal of Thoracic Oncology
20. ELIOS: A Multicenter, Molecular Profiling Study of Patients with EGFR -Mutant Advanced Non–Small Cell Lung Cancer Treated with First-Line Osimertinib
    Zofia Piotrowska, Myung‐Ju Ahn, Pei Jye Voon, Yong Kek Pang, Soon Hin How, S. Kim, Diego Luigi Cortinovis, Javier de Castro, Marcello Tiseo, Delvys Rodríguez‐Abreu et al. · 2026 · Cancer Discovery
21. Savolitinib ± Osimertinib in Japanese Patients with Advanced Solid Malignancies or EGFRm NSCLC: Ph1b TATTON Part C
    Kiyotaka Yoh, Tomonori Hirashima, Hideo Saka, Takayasu Kurata, Yuichiro Ohe, Toyoaki Hida, Anders Mellemgaard, Remy B. Verheijen, Xiaoling Ou, Ghada F. Ahmed et al. · 2021 · Targeted Oncology
22. Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib
    Maya N. White, Andrew J. Piper‐Vallillo, Rebecca M. Gardner, Kristen May Cunanan, Joel W. Neal, Millie Snigdha Das, Sukhmani Kaur Padda, Kavitha J. Ramchandran, Thomas T. Chen, Lecia Van Dam Sequist et al. · 2021 · Clinical Lung Cancer
23. A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer
    Sukhmani Kaur Padda, Karen L. Reckamp, Marianna Koczywas, Joel W. Neal, Jun Kawashima, Shengchun Kong, Daniel B. Huang, Mark Marion Kowalski, Heather A. Wakelee · 2021 · Cancer Chemotherapy and Pharmacology
24. Integrative molecular analysis of combined small-cell lung carcinomas identifies major subtypes with different therapeutic opportunities
    Michele Simbolo, Giovanni Centonze, Greta Alì, Giovanna Garzone, Sergio Vincenzo Taormina, Giovanna Sabella, Chiara Ciaparrone, Andrea Mafficini, Federica Grillo, Alessandro Mangogna et al. · 2021 · ESMO Open
25. Preclinical assessment of combination therapy of EGFR tyrosine kinase inhibitors in a highly heterogeneous tumor model
    Hiroshi Ikeuchi, Takeshi Hirose, Masachika Ikegami, Kazuya Takamochi, Kenji Suzuki, Hiroyuki Mano, Shinji Kohsaka · 2022 · Oncogene
26. Targeted therapy in lung cancer: Are we closing the gap in years of life lost?
    David Joseph Benjamin, Alyson Haslam, Jenny Gill, Vinay K. Prasad · 2022 · Cancer Medicine
27. Nanomedicine for targeting the lung cancer cells by interpreting the signaling pathways
    Mohammad Habeeb, Tasneem Abdul Kareem, Kolluru Lakshmi Deepthi, Vidyarani Sujitkumar Khot, You Huay Woon, Sarita Suryabhan Pawar · 2022 · Journal of Drug Delivery Science and Technology
28. Advances in the Lung Cancer Immunotherapy Approaches
    Hafiza Padinharayil, Reema Rose Alappat, Liji Maria Joy, Kavya V. Anilkumar, Cornelia M. Wilson, Alex George, Abilash Valsala Gopalakrishnan, Harishkumar Madhyastha, Thiyagarajan Ramesh, Ezhaveni Sathiyamoorthi et al. · 2022 · Vaccines
29. Combatting acquired resistance to osimertinib in EGFR-mutant lung cancer
    Jiyun Lee, Zofia Piotrowska, Ross Andrew Soo, Byoung Chul Cho, Sun Min Lim · 2022 · Therapeutic Advances in Medical Oncology
30. The complexity of EGFR exon 19 deletion and L858R mutant cells as assessed by proteomics, transcriptomics, and metabolomics
    Nobuaki Ochi, Masami Takeyama, Noriko Miyake, Maki Fuchigami, Hiromichi Yamane, Takuya Fukazawa, Yasunari Nagasaki, Tatsuyuki Kawahara, Hidekazu Nakanishi, Nagio Takigawa · 2023 · Experimental Cell Research
31. Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first- or second-generation tyrosine kinase inhibitors
    Chun‐Ta Huang, Chih-An Lin, Te-Jen Su, Ching‐Yao Yang, Tzu-Hsiu Tsai, Chia‐Lin Hsu, Wei‐Yu Liao, Kuan‐Yu Chen, Chao‐Chi Ho, Chong‐Jen Yu · 2023 · BMC Cancer
32. Chemotherapy for patients with EGFR-mutated NSCLC after progression on EGFR-TKI’s: Exploration of efficacy of unselected treatment in a multicenter cohort study
    Christi M. J. Steendam, Sophie M. Ernst, Sushil K. Badrising, Marthe S. Paats, Joachim G.J.V. Aerts, Adrianus Johannes De Langen, Anne‐Marie C. Dingemans · 2023 · Lung Cancer
33. Therapeutic role of EGFR - Tyrosine kinase inhibitors in non-small cell lung cancer with leptomeningeal metastasis
    Caiyan Jia, Qian Xu, Lu Zhao, Fanming Kong, Yingjie Jia · 2023 · Translational Oncology
34. SOS2 modulates the threshold of EGFR signaling to regulate osimertinib efficacy and resistance in lung adenocarcinoma
    Patricia L. Theard, Amanda J. Linke, Nancy E. Sealover, Brianna R. Daley, Johnny J. Yang, Katherine Cox, Robert L. Kortum · 2023 · Molecular Oncology
35. The trend toward more target therapy in pancreatic ductal adenocarcinoma
    Chiara Deiana, Margherita Agostini, Giovanni Brandi, Elisa Giovannetti · 2024 · Expert Review of Anticancer Therapy
36. Prediction of Epidermal Growth Factor Receptor Mutation Subtypes in Non–Small Cell Lung Cancer From Hematoxylin and Eosin–Stained Slides Using Deep Learning
    Wanqiu Zhang, Wei Wang, Yao Xu, Kun Wu, Jun Shi, Ming Li, Zheng-zhong Feng, Yinhua Liu, Yushan Zheng, Haibo Wu · 2024 · Laboratory Investigation
37. A Critical Review of the Impact of SMARCA4 Mutations on Survival Outcomes in Non-Small Cell Lung Cancer
    Peter Manolakos, Luigi Boccuto, Diana S. Ivankovic · 2024 · Journal of Personalized Medicine
38. Post-Progression Analysis of EGFR-Mutant NSCLC Following Osimertinib Therapy in Real-World Settings
    Ilaria Attili, Carla Corvaja, Gianluca Spitaleri, Pamela Trillo Aliaga, Ester Del Signore, Antonio Passaro, Filippo de Marinis · 2024 · Cancers
39. Biomarker testing in lung cancer: from bench to bedside
    Ullas Batra, Shrinidhi Nathany · 2025 · Oncology Reviews
40. Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group
    Mariano Provencio, Josefa Terrasa, Pilar Garrido, Rosario García Campelo, Francisco Aparisi, Pilar Díz, David Aguiar, Carlos García Girón, Julia Hidalgo, Carlos Aguado et al. · 2021 · BMC Cancer
41. HSP90 inhibition overcomes EGFR amplification‐induced resistance to third‐generation EGFR‐TKIs
    Sho Watanabe, Yasushi Goto, Hiroyuki Yasuda, Takashi Kohno, Noriko Motoi, Yuichiro Ohe, Hiroyoshi Nishikawa, Susumu S. Kobayashi, Kazuyoshi Kuwano, Yosuke Togashi · 2021 · Thoracic Cancer
42. Efficacy and safety of treatment modalities across EGFR selected/unselected populations with non-small cell lung cancer and brain metastases: A systematic review and Bayesian network meta-analysis
    Lihui Liu, Hua Bai, Samuel Seery, Sini Li, Chao Wang, Pei Xue, Jie Zhao, Jie Wang · 2021 · Lung Cancer
43. Comparison of Resistance Spectra after First and Second Line Osimertinib Treatment Detected by Liquid Biopsy
    Balázs Jóri, Stefanie Schatz, Len Kaller, Bettina Kah, Julia Roeper, H. Ramdani, Linda Diehl, Petra Hoffknecht, Christian Grohé, Frank Griesinger et al. · 2021 · Cancers
44. Iterative Upgrading of Small Molecular Tyrosine Kinase Inhibitors for EGFR Mutation in NSCLC: Necessity and Perspective
    Jing Zhu, Qian Yang, Weiguo Xu · 2021 · Pharmaceutics
45. Systematic review and meta-analysis of lung cancer brain metastasis and primary tumor receptor expression discordance
    Raees Tonse, Muni Rubens, Haley R. Appel, Martin C. Tom, Matthew David Hall, Yazmín Odia, Michael William McDermott, Manmeet Singh Ahluwalia, Minesh P. Mehta, Rupesh R Kotecha · 2021 · Discover Oncology
46. Patritumab Deruxtecan: Paving the Way for EGFR-TKI–Resistant NSCLC
    Sun Min Lim, Chang Gon Kim, Jii Bum Lee, Byoung Chul Cho · 2022 · Cancer Discovery
47. Real-world Afatinib Outcomes in Advanced Non–small Cell Lung Cancer Harboring EGFR Mutations
    Chi-Han Chen, John Wen‐Cheng Chang, Ching‐Fu Chang, Chen‐Yang Huang, Cheng‐Ta Yang, Chih‐Hsi S. Kuo, Yueh‐Fu Fang, Ping‐Chih Hsu, Chiao‐En Wu · 2022 · Anticancer Research
48. Three Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: Similarities and Differences
    Ling Chen, Yangqingqing Zhou, Chaosheng Gan, Xiaoli Wang, Yihui Liu, Chunhui Dong, Ruiyuan He, Jin Yang · 2022 · Cancer Investigation
49. The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan
    Yen-Hsiang Huang, Kuo-Hsuan Hsu, Jeng‐Sen Tseng, Tsung‐Ying Yang, Kun‐Chieh Chen, Kang‐Yi Su, Sung‐Liang Yu, Jeremy J.W. Chen, Gee‐Chen Chang · 2022 · Targeted Oncology
50. Metal-Tyrosine Kinase Inhibitors: Targeted metal-drug conjugates
    Darren Fergal Beirne, Martina Dalla Via, Trinidad Velasco‐Torrijos, Diego Montagner · 2022 · Coordination Chemistry Reviews
51. Lung Cancer with Brain Metastasis—Treatment Strategies and Molecular Characteristics
    S. Wang, Matan Uriel, Haiying Cheng · 2024 · Journal of Clinical Medicine
52. Real‐World Prevalence, Treatment Patterns, and Outcomes for Patients With HER2 (ERBB2)‐Mutant Metastatic Non‐Small Cell Lung Cancer, From a US‐Based Clinico‐Genomic Database
    Sarah Waliany, Misako Nagasaka, Leah Park, Clara J. K. Lam, Zoe Jiang, Feng Lin, Joel W. Neal · 2024 · Cancer Medicine
53. Remodeling of tumor microenvironments by EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer
    Soo-Min Kim, Jaemoon Koh, Tae Min Kim, Songji Oh, Soyeon Kim, Jeonghwan Youk, Miso Kim, Bhumsuk Keam, Yoon Kyung Jeon, Dong‐Wan Kim et al. · 2025 · iScience
54. Identifying the genomic landscape of EGFR-mutant lung cancers with central nervous system metastases
    J.A. Wilcox, Mark Yungjie Jeng, Samuel Tischfield, J.S.Y. Sui, D. Nemirovsky, Glenn Heller, Noura J. Choudhury, Jeff S. Ross, Charles M. Rudin, Gregory J. Riely et al. · 2025 · Annals of Oncology
55. Cost-Effectiveness of Tumor Genomic Profiling to Guide First-Line Targeted Therapy Selection in Patients With Metastatic Lung Adenocarcinoma
    Olivia M Dong, Pradeep J. Poonnen, David Winski, Shelby D. Reed, Vishal Vashistha, Jill S Bates, Michael J. Kelley, Deepak Voora · 2021 · Value in Health
56. New horizons for uncommon mutations in non-small cell lung cancer: BRAF, KRAS, RET, MET, NTRK, HER2
    Maria Eugenia Olmedo, Raquel Cervera, Luis Cabezón‐Gutiérrez, Yolanda Lage, E. Corral de la Fuente, Ana Gómez Rueda, Xabier Mielgo-Rubio, Juan Carlos Trujillo-Reyes, Felipe Couñago · 2022 · World Journal of Clinical Oncology
57. Radiotherapy with continued EGFR‐TKIs for oligoprogressive disease in EGFR‐mutated non‐small cell lung cancer: A real‐world study
    Chunhong Hu, Sixuan Wu, Renfang Deng, Yuanqiang Wu, Yue Pan, Long Shu, Fang Wu · 2022 · Cancer Medicine
58. Cancer Medicines: What Is Essential and Affordable in India?
    Manju Sengar, Adam Michael Fundytus, Wilma M. Hopman, Conjeevaram S. Pramesh, Venkatraman Srinivasan Radhakrishnan, Prasanth Ganesan, Aju Mathew, Dorothy Chilambe Lombe, Matthew Jalink, Bishal Gyawali et al. · 2022 · JCO Global Oncology
59. Circulating tumor DNA detection in MRD assessment and diagnosis and treatment of non-small cell lung cancer
    Xiaoxu Fang, Shaokun Yu, Yingying Jiang, Yan Xiang, Kaihua Lu · 2022 · Frontiers in Oncology
60. Sequential treatment in advanced non–small cell lung cancer harboring EGFR mutations
    Ping‐Chih Hsu, John Wen‐Cheng Chang, Ching‐Fu Chang, Chen‐Yang Huang, Cheng‐Ta Yang, Chih‐Hsi S. Kuo, Yueh‐Fu Fang, Chiao‐En Wu · 2022 · Therapeutic Advances in Respiratory Disease
61. Epidermal growth factor receptor inhibitors as adjuvant treatment for patients with resected non-small cell lung cancer harboring EGFR mutation: a meta-analysis of randomized controlled clinical trials
    Ning Zhao, Zhuo-peng Wu, Jie Yang, Weineng Feng, Shengli Yang, Ying Luo, Jun Ye, Fei Wang, Xiaowen Zhang, Ye Xiao et al. · 2023 · World Journal of Surgical Oncology
62. A Closer Look at EGFR Inhibitor Resistance in Non-Small Cell Lung Cancer through the Lens of Precision Medicine
    Martin Sattler, Isa Mambetsariev, Jeremy Fricke, Tingting Tan, Sariah Liu, Nagarajan Vaidehi, Evan P. Pisick, Tamara Mirzapoiazova, Adam Rock, Amartej Merla et al. · 2023 · Journal of Clinical Medicine
63. NSCLC in the Era of Targeted and Immunotherapy: What Every Pulmonologist Must Know
    Carley L. Mitchell, Annie Li Zhang, Débora S. Bruno, Francisco Aécio Almeida · 2023 · Diagnostics
64. First- versus Third-Generation EGFR Tyrosine Kinase Inhibitors in EGFR-Mutated Non-Small Cell Lung Cancer Patients with Brain Metastases
    Vineeth Tatineni, Patrick Joseph O'Shea, Ahmad Ozair, Atulya Aman Khosla, Shreya Saxena, Yasmeen Rauf, Xuefei Jia, Erin Sennett Murphy, Samuel T. Chao, John H. Suh et al. · 2023 · Cancers
65. Advancing oncology drug therapies for sub-Saharan Africa
    Kirthana Sharma, Tina M. Mayer, Sharon Li, Sadaf Qureshi, Faheem Farooq, Peter Vuylsteke, Tlotlo Bathethi Ralefala, Richard Marlink · 2023 · PLOS Global Public Health
66. Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results
    Edward B. Garon, Martin Reck, Kazuto Nishio, John Victor Heymach, Makoto Nishio, Silvia Novello, Luis G Paz-Ares, Sanjay Popat, Santiago Ponce-Aix, H. Graham et al. · 2023 · ESMO Open
67. Precision Oncology Comes of Age: Designing Best-in-Class Small Molecules by Integrating Two Decades of Advances in Chemistry, Target Biology, and Data Science
    Darrin D. Stuart, Angel Guzman-Perez, Natasja Brooijmans, Erica L. Jackson, Gregory V. Kryukov, Adam A. Friedman, Axel Hoos · 2023 · Cancer Discovery
68. Epigenetic-based combination therapy and liposomal codelivery overcomes osimertinib-resistant NSCLC via repolarizing tumor-associated macrophages
    Tingting Lin, Wei Xiong, Guihua Chen, Yang He, Long Li, Xinfu Gao, Jialin Zhou, Wen-wen Lv, Yongzhuo Huang · 2023 · Acta Pharmacologica Sinica
69. Impact on costs and outcomes of multi-gene panel testing for advanced solid malignancies: a cost-consequence analysis using linked administrative data
    Alberto Hernando‐Calvo, Paul Nguyen, Philippe Lucien Bedard, Kelvin Chan, Ramy Saleh, Deirdre Weymann, Celeste Yu, Eitan Amir, Dean A. Regier, Bishal Gyawali et al. · 2024 · EClinicalMedicine
70. Effect of the STK11 mutation on therapeutic efficacy and prognosis in patients with non-small cell lung cancer: a comprehensive study based on meta-analyses and bioinformatics analyses
    Ke Xu, Weinan Lu, Airu Yu, Hongwei Wu, Jie He · 2024 · BMC Cancer
71. Tyrosine kinase inhibitors in cancers: Treatment optimization – Part I
    David Combarel, L. Dousset, Stéphane Bouchet, Florent Ferrer, Pauline Tétu, Célèste Lebbé, Joseph Ciccolini, Nicolás Meyer, Angélo Paci · 2024 · Critical Reviews in Oncology/Hematology
72. Treatment sequences in EGFR mutant advanced NSCLC
    Mylène Wespiser, Aurélie Swalduz, Maurice Pérol · 2024 · Lung Cancer
73. Proteolysis Targeting Chimera Agents (PROTACs): New Hope for Overcoming the Resistance Mechanisms in Oncogene-Addicted Non-Small Cell Lung Cancer
    Nicoletta Cordani, Daniele Nova, Luca Sala, Maria Ida Abbate, Francesca Colonese, Diego Luigi Cortinovis, Stefania Canova · 2024 · International Journal of Molecular Sciences
74. CXCR1+ neutrophil infiltration orchestrates response to third-generation EGFR-TKI in EGFR mutant non-small-cell lung cancer
    Haowei Wang, Anwen Xiong, Xiaoxia Chen, Junhong Guo, Zhuoran Tang, Chunyan Wu, Shengxiang Ren, Caicun Zhou, Jian Chen, Likun Hou et al. · 2024 · Signal Transduction and Targeted Therapy
75. Non-small cell lung cancer
    Busayamas Chewaskulyong · 2025 · Elsevier eBooks
76. Resistance to First-line Osimertinib in EGFR-mutant NSCLC: Tissue is the Issue
    Zofia Piotrowska, Aaron N. Hata · 2020 · Clinical Cancer Research
77. Real-World Disease Burden and Outcomes of Brain Metastases in EGFR Mutation-Positive Non-Small-Cell Lung Cancer
    Eric Nadler, Janet L. Espirito, Melissa Pavilack, Bismark Baidoo, Ancilla W. Fernandes · 2020 · Future Oncology
78. The role of EGFR‐TKIs as adjuvant therapy in EGFR mutation‐positive early‐stage NSCLC : A meta‐analysis
    Chutong Lin, Fengling Hu, Hongling Chu, Peng Ren, Shanwu Ma, Jingdi Wang, Jie Bai, Xuan Han, Shaohua Ma · 2021 · Thoracic Cancer
79. Adjuvant therapy of operable nonsmall cell lung cancer: an update
    Tetsuya Mitsudomi, Junichi Soh · 2020 · Current Opinion in Oncology
80. Osimertinib for Front-Line Treatment of Locally Advanced or Metastatic EGFR-Mutant NSCLC Patients: Efficacy, Acquired Resistance and Perspectives for Subsequent Treatments
    Marc Guillaume Denis, Jaafar Bennouna · 2020 · Cancer Management and Research
81. Moving beyond epidermal growth factor receptor resistance in metastatic non-small cell lung cancer - a drug development perspective
    Julia E Lai-Kwon, Crescens Tiu, Abhijit Pal, Sachin Khurana, Anna Rachel Minchom · 2021 · Critical Reviews in Oncology/Hematology
82. Dealing with NSCLC EGFR mutation testing and treatment: A comprehensive review with an Italian real-world perspective
    Umberto Malapelle, Sara Pilotto, Francesco Passiglia, Francesco Pepe, Pasquale Pisapia, Luisella Righi, Angela Listì, Paolo Bironzo, Lorenzo Belluomini, Fabrizio Tabbò et al. · 2021 · Critical Reviews in Oncology/Hematology
83. Guaiazulene Triggers ROS-Induced Apoptosis and Protective Autophagy in Non-small Cell Lung Cancer
    Qin Ye, Li Zhou, Ping Jin, Lei Li, Shuwen Zheng, Zhao Huang, Jiayang Liu, Siyuan Qin, Hao Liu, Bingwen Zou et al. · 2021 · Frontiers in Pharmacology
84. Inferior outcome of bone metastasis in non-small-cell-lung-cancer patients treated with epidermal growth factor receptor inhibitors
    Yueyun Chen, Peipei Wang, Yang Fu, Qing Li, Jiangfang Tian, Ting Liu, Zhen Lin, Zhenyu Ding · 2021 · Journal of bone oncology
85. A real world analysis of first line treatment of advanced EGFR mutated non-small cell lung cancer: A multi-center, retrospective study
    Chung‐Shien Lee, Iman Ahmed, Emily Miao, Shirley Chung, Khilna Patel, Nina E. Kohn, Nagashree Seetharamu · 2021 · Journal of Oncology Pharmacy Practice
86. The role of molecular heterogeneity targeting resistance mechanisms to lung cancer therapies
    Ilaria Attili, Marzia Del Re, Elena Guerini‐Rocco, Stefania Crucitta, Pasquale Pisapia, Francesco Pepe, Massimo C.P. Barberis, Giancarlo Troncone, Romano Danesi, Filippo de Marinis et al. · 2021 · Expert Review of Molecular Diagnostics
87. Continuous Flow Synthesis of Anticancer Drugs
    Mara Di Filippo, Marcus Baumann · 2021 · Molecules
88. Effect of brain radiotherapy strategies on prognosis of patients with EGFR-mutant lung adenocarcinoma with brain metastasis
    Guangchuan Deng, Yingyun Zhang, Jiaojiao Ke, Qi Wang, Hongyue Qin, Jianbin Li, Zhenxiang Li · 2021 · Journal of Translational Medicine
89. Immunotherapy plus chemotherapy showed superior clinical benefit to chemotherapy alone in advanced NSCLC patients after progression on osimertinib
    Yaping Long, Qi Xiong, Qi Song, Yao Li, Xiaoyan Li, Boyu Qin, Ziwei Huang, Yi Hu, Bo Yeun Yang · 2021 · Thoracic Cancer
90. Regulation of Oncogenic Targets by Tumor-Suppressive miR-150-3p in Lung Squamous Cell Carcinoma
    Keiko Mizuno, Kengo Tanigawa, Shunsuke Misono, Takayuki Suetsugu, Hiroki Sanada, Akifumi Uchida, Minami Kawano, Kentaro Machida, Shunichi Asai, Shogo Moriya et al. · 2021 · Biomedicines
91. The impact of EGFR mutation status and single brain metastasis on the survival of non-small-cell lung cancer patients with brain metastases
    Yuya Fujita, Manabu Kinoshita, Tomohiko Ozaki, Koji Takano, Kei Kunimasa, Madoka Kimura, Takako Inoue, Motohiro Tamiya, Kazumi Nishino, Toru Kumagai et al. · 2020 · Neuro-Oncology Advances
92. A review of research progress on mechanisms and overcoming strategies of acquired osimertinib resistance
    Fanjie Qu, Yi Zhou, Weiwei Yu · 2021 · Anti-Cancer Drugs
93. Real-World Characteristics and Outcomes of Advanced Non-Small-Cell Lung Cancer Patients with EGFR Exon 19 Deletions or Exon 21 Mutations
    Katherine B. Winfree, Cliff Molife, Patrick M. Peterson, Yongmei Chen, Carla Visseren‐Grul, Mark S. Leusch, Julie Kay Beyrer, Anastasios Dimou · 2021 · Future Oncology
94. Efficacy of Adjuvant EGFR Inhibitors and Impact of Clinical Factors in Resected EGFR -mutated non-small-cell Lung Cancer: A Meta-Analysis
    Meichen Li, Xue Hou, Suxia Lin, Lie Zheng, Jianzhong Liang, Jing Chen, Na Wang, Baishen Zhang, Likun Chen · 2022 · Future Oncology
95. The value of disease-free survival (DFS) and osimertinib in adjuvant non-small-cell lung cancer (NSCLC): an international Delphi consensus report
    Maarten C. Hardenberg, B. Patel, Cecile Matthews, Raffaele Califano, Rosario García Campelo, Christian Grohé, Min Hee Hong, G. Liu, Shun Lü, Filippo de Marinis et al. · 2022 · ESMO Open
96. Pharmacokinetic/Pharmacodynamic Analysis of Savolitinib plus Osimertinib in an EGFR Mutation–Positive, MET-Amplified Non–Small Cell Lung Cancer Model
    Rhys D. O. Jones, Klas Petersson, Areya Tabatabai, Larry Bao, Helen K. Tomkinson, Alwin G. Schuller · 2023 · Molecular Cancer Therapeutics
97. Systematic review of time to subsequent therapy as a candidate surrogate endpoint in advanced solid tumors
    Paul‐Michael Agapow, Rob Mulla, Natasha Markuzon, Lone Harild Ottesen, Didier Meulendijks · 2023 · Future Oncology
98. Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small cell lung cancer in a real-world setting (OSI-FACT-EP)
    Yoshihiko Sakata, Go Saito, Shinya Sakata, Yuko Oya, Motohiro Tamiya, Hidekazu Suzuki, Ryota Shibaki, Asuka Okada, Toshihide Yokoyama, Hirotaka Matsumoto et al. · 2023 · Lung Cancer
99. Management of Treatment Resistance in Patients With Advanced Epidermal Growth Factor Receptor–Mutated Lung Cancer: Personalization, Parsimony, and Partnership
    Andrew J. Piper-Valillo, Hollis Viray, Jill Feldman, Deepa Rangachari · 2024 · Journal of Clinical Oncology
100. Quantification of cerebrospinal fluid tumor DNA in lung cancer patients with suspected leptomeningeal carcinomatosis
     Tej Deepak Azad, Shigeki Nanjo, Michael Chuwei Jin, Jacob J. Chabon, David Matthew Kurtz, Aadel A. Chaudhuri, Ian David Connolly, Angela Bik‐Yu Hui, Chih Long Liu, David J. Merriott et al. · 2024 · npj Precision Oncology